Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
OR

OTC · ORINY

Orion Oyj

Healthcare · Drug Manufacturers - General

$56.39

Down-$0.62 (-1.09%)

Updated Nov 5, 2026, 3:35 AM

SID Score

5.2/10

Composite research score

Smart Money

46/100

Neutral

Market cap
19.4B
P/E ratio
27.13
Dividend yield
1.66%
52-week range
— – —
Volume
100
Avg. volume
170

Price performance · ORINY

ORINY price history

1M range · 0 trading sessions · Daily adjusted prices

ORINY does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest ORINY news

The latest Smart Investors Daily articles mentioning ORINY.

Stock researchCompany · Overview

ORINY research

Overview

Company profile and research snapshot.

Company profile

ORION CORP NEW UNSP/ADR

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

Orion Oyj (HLSE:ORNBV) Stock Richly Valued Despite Q3 Earnings Surge

Orion Oyj stock closed at €95.95 on 28 October, capping a strong run over the past quarter, just as Q3 2026 numbers landed. The headline is simple. Earnings kept tracking higher while the valuation still sits on a P/E of 20.4x that compares to a higher European pharmaceuticals industry average and much richer peers. Short term traders are reacting to a good quarter. Long term investors are staring at a different picture, one where a discounted cash flow estimate of €218.01 and a 30.3% net...

Yahoo · Oct 28, 2026

Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline

ORION CORPORATION INTERIM REPORT 1–9/2026 28 OCTOBER 2026 at 12:00 EET Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline July–September 2026 Highlights Net sales totalled EUR 542.2 (July–September 2025: 423.2) million Operating profit was EUR 209.9 (121.0) millionBasic earnings per share were EUR 1.19 (0.68)Cash flow from operating activities per share was EUR 0.68 (0.55)Phase 1 initiated with ODM-216, Orion's first biol

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By